PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer

NCT03971214

PHASE1INTERVENTIONAL

Chinese Academy of Medical Sciences

6 participants

Started 2019-06 · Completed 2021-06

Status: Unknown (as of 12-23-2025)

Conditions

Extensive-stage Small Cell Lung CancerRadiotherapyImmunotherapy

Interventions

DRUG: PD-1 inhibitor JS-001

Linked Papers (from SciSciNet-V2)

Total Papers32

Background

14

Result

0

Derived

0

Unknown

18

View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

The prognosis of extensive-stage small cell lung cancer is still very poor, even for those who received platinum-based chemotherapy and chest radiotherapy. 2-year survival rate of these patients is only about 10%. Therefore, this study aims to explore a comprehensive treatments with low toxicity to further improve the efficacy for these paitents with PD-1 inhibitor.

Sort by:

Background Papers28

The blockade of immune checkpoints in cancer immunotherapy

12,062 citations

The blockade of immune checkpoints in cancer immunotherapy

12,062 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

8,603 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

8,603 citations

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

2,879 citations

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

2,879 citations

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

1,988 citations

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

1,988 citations

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

1,846 citations

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

1,846 citations

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody

1,480 citations

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody

1,480 citations

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

Maximizing Tumor Immunity With Fractionated Radiation

Maximizing Tumor Immunity With Fractionated Radiation

Cancer incidence and mortality in China in 2013: an analysis based on urbanization level

Cancer incidence and mortality in China in 2013: an analysis based on urbanization level

The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology

The Confluence of Stereotactic Ablative Radiotherapy and Tumor Immunology

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers18

Global cancer statistics, 2012

26,048 citations

Pembrolizumab versus Ipilimumab in Advanced Melanoma

5,239 citations

PD-1 and Its Ligands in Tolerance and Immunity

4,838 citations

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

1,745 citations

Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide

1,394 citations

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

1,168 citations

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

1,120 citations

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

Developmentally regulated expression of the PD-1 protein on the surface of double-negative(CD4^–CD8^–) thymocytes

Effect of Host Immune Capability on Radiocurability and Subsequent Transplantability of a Murine Fibrosarcoma<xref ref-type="fn" rid="FN2">2</xref>

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America